GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...

In a report released today, James Gordon from J.P. Morgan reiterated a Sell rating on GlaxoSmithKline (GSK – Research Report). The company’s ...

Stocks in London are set to open lower on Tuesday, with a eurozone inflation reading, and US data in focus. Both batches of data will be scrutinised for what they could mean for the European Central ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the settlements, which will be funded through "existing resources," and said there ...

has been found guilty of conspiracy to steal trade secrets in relation to medicines under development at GSK between January 2010 and January 2016. He is the brother of Yu Xue, who worked as a ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...

GSK's Nucala approved in China for CRSwNP, affecting 1/3 of 107 million sinusitis patients; third IL-5 condition indication in the region. Phase 3 trial shows Nucala reduces COPD exacerbations ...

(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study. The London-based ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.